# Source: Blackrock Neurotech and the Utah Array

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Industry Press
**URL:** https://www.medicaldesignandoutsourcing.com/utah-array-brain-computer-interface-blackrock-neurotech/
**Publisher:** Medical Design & Outsourcing
**Accessed:** 2026-05-09
**Updated:** 2026-05-09

## Summary

Industry-press coverage of Blackrock Neurotech's Utah Electrode Array, including its development history at the University of Utah, current clinical use, FDA Breakthrough Device designation for the MoveAgain motor BCI system, and the next-generation Neuralace flexible-mesh device.

## Useful Claims

- The Utah Array gathers neural signals across up to 96–100 electrode channels per device.
- Public coverage describes more than 30,000 cumulative patient-days of human implantation across paralysis and ALS studies.
- MoveAgain has FDA Breakthrough Device designation as a motor-cortex BCI for restoration of device control.
- Neuralace is described in public coverage as a flexible array with more than 10,000 channels.

## Reliability Notes

Reasonable secondary source for the company's public technical positioning. Not a primary clinical evidence source. Some claim language echoes Blackrock marketing materials and should be triangulated against peer-reviewed publications and FDA documents before being relied on for clinical assertions.

## Related Pages

- [Blackrock Neurotech](blackrock-neurotech.md)